See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for ...

Summary by The Record
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:

7 Articles

Hastings TribuneHastings Tribune
Center

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for ...

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:

Read Full Article
The RecordThe Record
Lean Left

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel Ahr Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:

·Waterloo, Canada
Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Dr. Falk Pharma, Allianthera sign agreement for ATB102

Dr. Falk Pharma signed an agreement with Allianthera (Suzhou) Biopharmaceuticals to co-develop, license, manufacture, commercialise ATB102.

Read Full Article
ADKhabarADKhabar

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:  Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis  Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, Allianthera (Suzhou) Biopharmaceuticals Co., […] The post Dr. Falk Phar…

Read Full Article
thailandtribune.comthailandtribune.com

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel Ahr Agonist Development – Thailand Tribune

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis  Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, Allianthera (Suzhou) Biopharmaceuticals Co., ...

Read Full Article
swazilandonlinenews.comswazilandonlinenews.com

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development – Swaziland Online News

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis  Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, Allianthera (Suzhou) Biopharmaceuticals Co., […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Record broke the news in Waterloo, Canada on Wednesday, July 30, 2025.
Sources are mostly out of (0)

Similar News Topics

Freiburg icon

Freiburg

News
For You
SearchBlindspotLocal